WellDoc’s digital diabetes management therapeutic BlueStar will now be available on the Solera network as a diabetes management option.

Phoenix, Arizona-based Solera Health, a platform which offers a marketplace for chronic disease management programs, and digital therapeutic maker WellDoc announced the partnership today, and said that the partnership aligns both companies' goals to improve the health of those living with chronic disease by enhancing clinical outcomes and overall health. 

“The addition of BlueStar to our network of evidence-based solution providers enables Solera to offer a broader, more comprehensive approach to diabetes prevention and management that drives sustained consumer engagement and clinical outcomes,” Brenda Schmidt, CEO of Solera Health, said in a statement. “WellDoc is an ideal partner to help fill this need as BlueStar delivers impressively on both — individual commitment and clinically validated results — as evidenced by the data we’ve seen to date.”

Solera Health connects patients, payers, and physicians with community organizations and digital therapeutics providers. It has made partnerships with other mobile diabetes management offerings in the past. In 2016 Solera announced a partnership with Yes Health, a mobile diabetes prevention program that links people at risk for developing Type 2 diabetes to one-on-one coaches, nutrition advice, and fitness trackers. 

Solera was founded in 2015 and currently has raised just over $30 million in funding, according to Crunchbase. In February of 2017, it earned certified status from the Health Information Trust Alliance, which validates Solera’s health plan for employer and health system clients, and confirms that the company meets the highest industry standards in protection and risk management of healthcare information and complies with state and federal laws. 

The FDA-cleared BlueStar diabetes management system analyzes patient data, compares data trends, and sends analytics to the patient’s healthcare team. It also features behavioral coaches, motivational messages, educational content, and tools for population health engagement. 

WellDoc’s 2018 has been off to a busy start. Earlier this month the company announced its partnership with Voluntis to combine their technologies and offer joint products in the future. Voluntis’ app, called Insulia, provides dosage recommendations, educational coaching, and diabetes-related data. 

A recent analysis contracted by WellDoc found that the BlueStar could lead to an average savings of more than $250 per patient per month. 

WellDoc is also one of the founding members of the Digital Therapeutics Alliance, an organization founded late last year that pledges to work together to promote real-world evidence studies and pilot programs, create industry standards, and develop shared data stores. 

“We’re honored to join Solera Health’s network of preferred digital therapeutic solution providers for diabetes management,” Kevin McRaith, WellDoc President and CEO, said in a statement. “Partnering with Solera Health is a natural next step as we continue to expand access to BlueStart via health plans, health systems, and employers.”